PTC soars on CHMP nod for Translarna
This article was originally published in Scrip
Executive Summary
Shares in PTC Therapeutics shot up by as much as 117% to $33.18 on news that its novel treatment for Duchenne muscular dystrophy Translarna (ataluren) has finally received the go-ahead for approval from the EU's CHMP.
You may also be interested in...
PTC Tumbles On Ataluren Failure In Cystic Fibrosis
With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.